Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Safety and tolerability of moxifloxacin in pediatric population: A systematic review of evidence-based practice

Mohammed Kanan Alshammari¹ , Noura Abdullah AlAtwi², Wejdan Mohammed Alshehri³, Shatha Khaled Altwijri⁴, Sama Abdulmohsen Alsheehe⁵, Abdulaziz Khalaf Alshammari⁶, Rehab Raja Alroqi⁷, Raghad Othman Alsharafi⁸, Razan Ali Alshehri⁹, Khalid Mokhlef Alenazi¹⁰, Faisal Shouick Alenazi¹⁰, Nasser Hamdan Alenazy¹⁰, Faisal Saleem Alanazi¹⁰, Mujtaba Abbas Jasim Aljasim¹¹, Fatimah Raja Alahmari¹²

¹Department of Clinical Pharmacy, King Fahad Medical City, Riyadh 12211, Kingdom of Saudi Arabia; ¹⁰King Khalid General Hospital, Ministry of Health, Hafar Al-batin 31991, Kingdom of Saudi Arabia; ¹¹Department of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Kingdom of Saudi Arabia; ¹²Department of Pharmacy, Khamis Mushait General Hospital, South Region, Khamis Mushait 62567, Kingdom of Saudi Arabia. ²Pediatric Department, at East Jeddah General Hospital, Sabt Alalayah General Hospital, South Region, Sabat Alalayah 62463, Kingdom of Saudi Arabia; ³Department of Radiology, Sabt Alalayah General Hospital, South Region, Sabat Alalayah 62463, Kingdom of Saudi Arabia; ⁴Buraydah Colleges, College of Pharmacy, Central Region, Qassim 52584, Kingdom of Saudi Arabia; ⁵Department of Clinical Pharmacy, Alqassim University, Unaizah 51911, Kingdom of Saudi Arabia; ⁶College of Pharmacy, Northern Border University, Hafar Al-Batin 31991, Kingdom of Saudi Arabia; ⁷College of Pharmacy, Shaqra University, Al-dawadmi 17451, Kingdom of Saudi Arabia; ⁸Department of Pharmacy, King Khalid University, Abha 62523, Kingdom of Saudi Arabia; ⁹Department of Pharmacy, Taif University, Taif 21944, Kingdom of Saudi Arabia;

For correspondence:- Mohammed Alshammari Email: ii_kanan101@outlook.com

Accepted: 7 March 2024 Published: 31 March 2024

Citation: Alshammari MK, AlAtwi NA, Alshehri WM, Altwijri SK, Alsheehe SA, Alshammari AK, et al. Safety and tolerability of moxifloxacin in pediatric population: A systematic review of evidence-based practice. Trop J Pharm Res 2024; 23(3):641-652 doi: 10.4314/tjpr.v23i3.20

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the adverse events (AEs) associated with moxifloxacin (MFX) use in children below the age of 18 years.

Methods: This review was performed in conformity with the preferred items for systematic reviews and meta-analysis (PRISMA) guidelines using different databases. Articles meeting the inclusion criteria were screened and the studies were selected for the qualitative synthesis.

Results: A total of 21 studies were included in the systematic review. Among these, 7 retrospective cohort studies, 6 case reports, 3 prospective cohort studies, 2 randomized clinical trials (RCT) and the remainder utilized other methodologies. The variability in studies allowed for an assessment of the safety and tolerability of both short-term and long-term MFX administration in pediatric patients.

Conclusion: Although MFX use is associated with AEs, the majority were mild and resolved on their own. The reason for QTc prolongation and elevated liver enzymes remain a question for clinicians in prescribing MFX in pediatric patients.

Keywords: Moxifloxacin (MFX), Community-acquired pneumonia (CAP), Adverse effects (AEs), Randomized clinical trials (RCT)